The course is designed for physicians, nurses, pharmacists, and field staff who are interested in a multidisciplinary approach to tuberculosis (TB) care. This four-day intensive course will familiarize the clinician with all the aspects of tuberculosis infection, disease and clinical care using an interdisciplinary and interactive approach.
The TB course is intended as a refresher course for physicians (both public and private) that may be involved in the management and care of patients with TB. The course is developed as a preparation course to the WMA MDR-TB course and together both courses offer a complete summary of the management of TB.
Full
AnswerMDR-TB
Multidrug-resistant tuberculosis (MDR-TB) is a form of tuberculosis (TB) infection caused by bacteria that are resistant to treatment with at least two of the most powerful first-line anti-TB medications (drugs), isoniazid and rifampin.
https://en.wikipedia.org › Multidrug-resistant_tuberculosis
What is the tuberculosis basics eLearning course?
This is an updated version of the Tuberculosis Basics eLearning course. It provides some basic information about tuberculosis (TB) and its global impact, along with an overview of some strategies that are currently under way to control TB.
Where can I get training on tuberculosis (TB)?
Training courses Training courses on tuberculosis (TB) are offered through WHO collaborating centres and partners. The WHO Sondalo Training course on the implementation of the new WHO End-TB strategy WHO Collaborating Centre on prevention and control of tuberculosis in Penitentiary System
What is the treatment for tuberculosis?
Treatment TB is a treatable and curable disease. Active, drug-susceptible TB disease is treated with a standard 6-month course of 4 antimicrobial drugs that are provided with information and support to the patient by a health worker or trained volunteer. Without such support, treatment adherence is more difficult.
What are the key facts about tuberculosis?
Key facts. Ending the TB epidemic by 2030 is among the health targets of the Sustainable Development Goals. Tuberculosis (TB) is caused by bacteria (Mycobacterium tuberculosis) that most often affect the lungs. Tuberculosis is curable and preventable. TB is spread from person to person through the air.
How long is the course of TB?
You'll be prescribed at least a 6-month course of a combination of antibiotics if you're diagnosed with active pulmonary TB, where your lungs are affected and you have symptoms. The usual treatment is: 2 antibiotics (isoniazid and rifampicin) for 6 months.
WHO guidelines TB prevention?
The World Health Organization has updated its guidelines on tuberculosis preventive treatment. Among the 18 recommendations, the group now conditionally recommends shorter regimens as alternative treatment options: 1 month of daily rifapentine and isoniazid, or 4 months of daily rifampicin.
What is the short course treatment given to the tuberculosis?
CDC and the National Tuberculosis Controllers Association (NTCA) preferentially recommend short-course, rifamycin-based, 3- or 4-month latent TB infection treatment regimens over 6- or 9-month isoniazid monotherapy. Short course regimens include: Three months of once-weekly isoniazid plus rifapentine (3HP)
What are the 3 types of tuberculosis?
Tuberculosis is a bacterial infection that usually infects the lungs. It may also affect the kidneys, spine, and brain. Being infected with the TB bacterium is not the same as having active tuberculosis disease. There are 3 stages of TB—exposure, latent, and active disease.
WHO guideline on TB treatment?
Standards for treating drug-susceptible TB The initial phase should consist of 2 months of isoniazid, rifampicin, pyrazinamide and ethambutol. The continuation phase should consist of 4 months of isoniazid and rifampicin. Daily dosing should be used throughout treatment.
How long is TB prophylaxis?
A one-month antibiotic regimen to prevent active tuberculosis (TB) disease was at least as safe and effective as the standard nine-month therapy for people living with HIV, according to the results of a large international clinical trial.
Can TB be cured in 2 months?
Brief Summary: Tuberculosis (TB) is a serious infection that can affect the lungs and other parts of the body. The usual way to treat TB is to take 4 medicines by mouth every day for 2 months, then take 2 of the same medicines for 4 more months, for a total of 6 months.
Can TB be cured in 3 months?
After taking TB medicine for several weeks, a doctor will be able to tell TB patients when they are no longer able to spread TB germs to others. Most people with TB disease will need to take TB medicine for at least 6 months to be cured.
Who latent TB Guidelines 2020?
Preferred RegimensThree Months of Weekly Isoniazid Plus Rifapentine. ... Four Months of Daily Rifampin. ... Three Months of Daily Isoniazid Plus Rifampin.
What are the 4 stages of TB?
TB infection happens in 4 stages: the initial macrophage response, the growth stage, the immune control stage, and the lung cavitation stage. These four stages happen over roughly one month.
How do TB symptoms start?
Signs and symptoms of active TB include: Coughing for three or more weeks. Coughing up blood or mucus. Chest pain, or pain with breathing or coughing.
Who is most at risk for tuberculosis?
At-Risk Populations for Tuberculosis Foreign-born persons, including children, who have immigrated within the last 5 years from areas that have a high TB incidence. Residents and employees of high-risk congregate settings (prisons, nursing homes, homeless shelters, drug treatment facilities, and healthcare facilities)
Course information
This e-learning course was developed by WHO. It is a comprehensive, self-paced online course that follows the content of the WHO operational handbook on tuberculosis. Module 4: drug-resistant tuberculosis treatment.
What you'll learn
select the appropriate treatment regimen for drug-resistant TB (shorter or longer) for eligible patient groups, taking into consideration the needs of various subgroups, the country context, epidemiological background, patient’s history and results of drug-susceptibility testing;
Who this course is for
This e-learning course is intended for persons who provide guidance to countries on the uptake of WHO guidelines; for example managers of national tuberculosis (TB) programmes, technical staff at ministries of health, WHO staff, staff of technical agencies, consultants and anyone supporting countries and major subnational units in the development and implementation of drug-resistant TB policies and guidelines.
Improving detection of drug-resistant TB is crucial to eliminate TB
DR-TB, a major threat for global health, particularly affects the WHO European Region where the proportion of DR-TB among new and previously treated TB patients significantly exceeds the global average. DR-TB is a result of the inadequate treatment of TB and/or poor airborne infection prevention in health care facilities and congregate settings.
A unique combination of practical guidance and expert advice
Participants can exchange experiences in course forums and benefit from laboratory experts that are available to address their key questions through the forums and a dedicated pilot email service.
About OpenWHO
OpenWHO is WHO’s interactive, web-based platform that offers online courses to people who are preparing to work, or are already working, in epidemics, pandemics and health emergencies.
Objective
When you have completed this eLearning course, you will have a better understanding of:
Credits
We greatly appreciate the invaluable help from the following individuals in developing this course:
Who Is Most at Risk?
- Tuberculosis mostly affects adults in their most productive years. However, all age groups are at risk. Over 95% of cases and deaths are in developing countries. People who are infected with HIV are 18 times more likely to develop active TB (see TB and HIV section below). The risk of active …
Global Impact of TB
- TB occurs in every part of the world. In 2020, the largest number of new TB cases occurred in the WHO South-East Asian Region, with 43% of new cases, followed by the WHO African Region, with 25% of new cases and the WHO Western Pacific with 18%. In 2020, 86% of new TB cases occurred in the 30 high TB burden countries. Eight countries accounted for two thirds of the new TB case…
Symptoms and Diagnosis
- Common symptoms of active lung TB are cough with sputum and blood at times, chest pains, weakness, weight loss, fever and night sweats. WHO recommends the use of rapid molecular diagnostic tests as the initial diagnostic test in all persons with signs and symptoms of TB as they have high diagnostic accuracy and will lead to major improvements in the early detection of TB …
TB and HIV
- People living with HIV are 18 (Uncertainty interval: 15-21) times more likely to develop active TB disease than people without HIV. HIV and TB form a lethal combination, each speeding the other's progress. In 2020, about 215 000 people died of HIV-associated TB. The percentage of notified TB patients who had a documented HIV test result in 2020 was only 73%, up from 70% in 2019. In th…
Multidrug-Resistant TB
- Anti-TB medicines have been used for decades and strains that are resistant to one or more of the medicines have been documented in every country surveyed. Drug resistance emerges when anti-TB medicines are used inappropriately, through incorrect prescription by health care providers, poor quality drugs, and patients stopping treatment prematurely. Multidrug-resistant tuberculosi…
Catastrophic Cost
- WHO’s End TB Strategy target of “No TB patients and their households facing catastrophic costs as a result of TB disease”, monitored by countries and WHO since WHA67.1 End TB Strategy was adopted in 2015, shows that the world did not reach the milestone of 0% by 2020. According to the results of 23 national surveys on costs faced by TB patients and their families, the percentag…
Investments in TB Prevention, Diagnosis and Treatment and Research
- US$ 13 billion are needed annually for TB prevention, diagnosis, treatment and care to achieve global targets agreed on UN high level-TB meeting. 1. Investments in TB prevention, diagnosis and care for tuberculosis in low- and middle-income countries (LMICs) accounting for 98% of reported TB cases, fall far short of what is needed. Less than half (41%) of the global TB funding target is …
Global Commitments and The Who Response
- On 26 September 2018, the United Nations (UN) held its first- ever high-level meeting on TB, elevating discussion about the status of the TB epidemic and how to end it to the level of heads of state and government. It followed the first global ministerial conference on TB hosted by WHO and the Russian government in November 2017. The outcome was a political declaration agree…
Popular Posts:
- 1. which machines can use a private switch? course hero
- 2. where to host your online course
- 3. what are course should you like go into anesthesia
- 4. how much does a dui course cost
- 5. how to add a new course in mheducation connect
- 6. how to move files from course to course canvas
- 7. how to host an obstacle course
- 8. where is the warewolf agility course
- 9. after a course of antibiotics how long do they stay in your system
- 10. where is payne's valley golf course